NCT06361576View on ClinicalTrials.gov

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

CompletedOBSERVATIONAL
Enrollment

700

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

January 25, 2024

Study Completion Date

January 25, 2024

Conditions
Upper Gastrointestinal Cancer
Interventions
DRUG

Nivolumab

As per product label

Trial Locations (1)

L5K 2L3

Bayshore Specialty Rx Ltd., Mississauga

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06361576 - Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada | Biotech Hunter | Biotech Hunter